NCT02734693View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

PHASE3CompletedINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Attention-Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG

dasotraline 4mg

dasotraline 4mg/day

OTHER

Placebo

placebo/day

Trial Locations (5)

32751

Florida Clinical Research Center, LLC, Maitland

34201

Meridien Research, Bradenton

77007

Bayou City Research, Ltd, Houston

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

92660

Avida Inc, Newport Beach

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT02734693 - A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. | Biotech Hunter | Biotech Hunter